The intake of oral semaglutides such as Wegovy or Rybelsus among adults with type 2 diabetes (T2D) was associated with a reduced risk of heart failure (HF) compared to those who took a placebo, ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help ...

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults ...

Patients with a heart failure history and preserved ejection fraction appeared to benefit ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral semaglutide compared with placebo as an adjunct to standard of care for the ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. Oral semaglutide ...

Rybelsus (semaglutide) is a brand-name oral tablet that’s prescribed for type 2 diabetes. The cost of the drug with and without insurance can depend on several factors, such as whether Rybelsus has a ...

RYBELSUS ® (semaglutide tablets) is approved to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 ...

Rybelsus is a pill form version of semaglutide – an FDA approved prescribed medication to manage blood sugar levels in patients with type 2 diabetes. Another effect that Rybelsus has is that it can ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026.